324 results about "Galactosucrose" patented technology

The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1,3-galactose, a known red meat allergen, and methods for use thereof.

The invention discloses a composition for regulating sleep rhythm homeostasis as well as a preparation method and application thereof. The composition for regulating the sleep rhythm homeostasis is prepared from the following components in percentage by weight: 5 to 18 percent of polydextrose, 9 to 15 percent of galactooligosaccharide, 1 to 10 percent of inulin, 0.4 to 2 percent of gamma-aminobutyric acid, 0.8 to 2.2 percent of L-theanine, 0.1 to 3.5 percent of magnesium citrate, 2 to 21 percent of semen ziziphi spinosae extract, 1 to 10 percent of poria cocos extract, 0.5 to 2 percent of pericarpium citri reticulatae extract, 0.3 to 1 percent of liquorice root extract and 15 to 40 percent of maltodextrin. 5-18% of coconut oil powder MCTs, and 0.5-2% of a lily extract. According to the application, a magnesium MCTs shell-core structure is delivered by maltodextrin to form a mitochondrial piezoelectric engine so as to improve prebiotics, promote flora metabolism efficiency and energy supply feedback, activate intestinal pheochromophilic cells and improve SLC6A4 gene expression so as to improve synthesis of 5-hydroxytryptamine in the brain and activate GABA energy neurons; meanwhile, through the spina date seed and poria cocos quantum dots and a pericarpium citri reticulatae and liquorice pi-pi stacking network, the blood-brain barrier penetration rate is greatly increased, and hypothalamic CRH release is adjusted.

The invention relates to the technical field of functional food, in particular to immune regulation type prebiotic syrup with synergy of galactomannan. The active components of the composite solid beverage are prepared from the following raw materials in percentage by weight: 20%-35% of fructo-oligosaccharide, 10%-18% of galactooligosaccharide, 8%-15% of stachyose, 3%-7% of xylooligosaccharide, 5%-12% of lactitol, 5%-10% of galactomannan, 2%-5% of yeast beta-glucan and 1%-3% of N-acetylglucosamine. The composition further comprises 4-8% of inulin and 3-6% of resistant dextrin as a matrix filling and slow-release carrier, and the sum of the weight percentages of all the active ingredients and the carrier is 100%. By remodeling intestinal microecology and inhibiting inflammation pathways, the intestinal inflammation state can be remarkably improved, expression of intestinal mucosa tight junction protein is promoted, and an innovative solution is provided for people suffering from chronic bowel diseases and immune imbalance.

The invention relates to the use of beta1,3′-galactosyllactose for improving the gut barrier function. This can in particular be administered to subjects at risk for increased gut barrier permeability, preferably infants and young children.

The invention belongs to the technical field of biochemistry, and particularly relates to a probiotic composition for relieving depression as well as a preparation method and application of the probiotic composition. The probiotic composition is prepared from bacillus cecum, lactobacillus reuteri and an oligosaccharide composition; wherein the viable count of the bacillus cecum and the lactobacillus reuteri is 10 < 9 >-10 < 11 > CFU / g; the oligosaccharide composition is prepared by compounding polydextrose, fructo-oligosaccharide and galactooligosaccharide according to an optimized weight ratio. According to the invention, the oligosaccharide composition is cooperated with the probiotics to play a curative effect, so that the proliferation effect of the bacteroides cecum and the lactobacillus reuteri in the intestinal tract is improved, and the balance of the probiotics in the intestinal tract is regulated. Detection results of behavioristics and physiological indexes of mice show that the depression-like behaviors of the mice are remarkably reduced under the action of the composition, and various biochemical indexes are remarkably improved; the composition has a certain improvement effect on depressive mood.

The invention provides curcumin composite particles for improving alcohol-related liver diseases and a preparation method of the curcumin composite particles, and belongs to the technical field of nutritional active ingredient delivery systems. According to the preparation method, zein is taken as a core carrier, curcumin encapsulation is realized through an anti-solvent precipitation method, a compact gel middle layer is constructed by further adopting the protection performance of carrageenan and combining calcium ion mediated ionic crosslinking, and then the outer layer is coated with galactosylated chitosan with liver targeting property through electrostatic adsorption, so that the curcumin-containing hydrogel is prepared. And the curcumin-zein-carrageenan-galactosylated chitosan composite particle with a core-shell-shell structure is innovatively constructed. Compared with free curcumin, the composite particle has obviously improved light and heat stability, realizes controlled release of curcumin in a gastrointestinal tract environment, exerts an effect of obviously improving the alcohol-related liver disease, and has a good application prospect in the aspect of development of functional products for preventing and treating the alcohol-related liver disease.

The invention relates to the technical field of culture media, and particularly discloses a candida chromogenic culture medium as well as a preparation method and application thereof. The candida chromogenic culture medium disclosed by the invention is prepared from the following components in concentration: 10 to 11 g / L of peptone, 12 to 17 g / L of agar, 7 to 9 g / L of glucose, 1 to 2 g / L of chromogenic substrate and 0.4 to 0.6 g / L of bacteriostatic agent, the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D-galactosamine and 4-methylumbelliferone-beta-D-N-acetyl galactosamine, and the chromogenic substrate is formed by mixing heavy 4-nitrophenyl-N-acetyl-beta-D- The bacteriostatic agent is prepared by mixing chloramphenicol, taurocholic acid and nalidixic acid. When being used for detecting and identifying candida albicans, candida tropicalis, candida krusei and candida glabrata, the chromogenic culture medium provided by the invention has strong specificity, short identification time and wide practical application value.

The invention discloses a functional additive composition for animal food. The functional additive composition is prepared from coenzyme Q10, glutamic acid, galactooligosaccharide, fructus lycii powder and the balance of food-grade carrier. The components of the composition cooperate with each other, so that the composition can support the effects of enhancing the physique vitality of animals, promoting nutrient absorption, helping to maintain a healthy intestinal environment and the like, has remarkable innovativeness and practicability, and is expected to create good benefits in the field of animal foods. The invention can be used in economic animals and pet animals.

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

This invention discloses an arabinogalactan sulfate derived from *Streptococcus filamentosa*, its preparation method, and its applications, belonging to the fields of natural product chemistry and marine biological resource development technology. The technical solution includes an arabinogalactan sulfate derived from *Streptococcus filamentosa*, with a monosaccharide composition comprising arabinose, galactose, and rhamnose, the molar percentage of arabinose being not less than 70%; the main chain backbone is modified with natural sulfate groups, with the sulfate groups replacing at least one hydroxyl site of the arabinose residues. This invention, when applied to anticoagulation, exhibits good safety and a significant anticoagulant effect.

The present invention relates to recellularization of xenogeneic tissue. Specifically, the present invention relates to recellularization of xenogeneic tissue, which enables transplantation of non-immunogenic biological tissue with improved durability and regenerative capacity by generating xenogeneic tissue having regenerative capacity through human cell recellularization after removal of galactose-alpha-1,3-galactose (α-Gal) xenoantigens and non-galactose (non-Gal) xenoantigens.

The invention relates to the technical field of biochemistry, and particularly discloses a galactosyl zinc-porphyrin derivative and a preparation method and application thereof.The galactosyl zinc-porphyrin derivative is formed by coupling a group with double functions of fluorescence and cytotoxic activity and a liver cancer targeting group, can be specifically combined with a liver cancer cell HepG2, emits 608 nm and 659 nm fluorescence signals under the excitation wavelength of 425 nm, and can be used for detecting liver cancer. And accurate tracing can be realized. Meanwhile, IC509.1 mu M + / -2.59 is used for killing liver cancer cells, so that targeted therapy is realized. The chemical disclosed by the invention has the functions of fluorescence tracing and targeted killing, can synchronously realize accurate positioning (fluorescence tracing) and efficient removal (targeted treatment) of liver cancer cells without drug combination, can be used for liver cancer diagnosis, treatment and curative effect evaluation, and has extremely high research and development value.

The present invention provides a nutritional composition comprising one or more of vitamin D, polydextrose and galacto-oligosaccharides in combination with a calcium source. The composition has the effect of improving the intestinal mucosal barrier including improving intestinal mucosal permeability, modulating expression of intercellular tight junction proteins, improving intestinal mucosal tissue structure and improving levels of markers of the intestinal mucosal barrier.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

The invention provides an aerosol-type face pack cosmetic that, when dispensed, forms a flexible, easy-to-use, and low-irritation resin foam that easily adheres to the face, such as around the eyes and nose. It also allows the fermented liquid contained in the resin foam to easily seep out, making it easy to apply the fermented liquid to the face and less likely to cause tightness. [Solution] An aerosol pack cosmetic comprising a beauty serum and dimethyl ether, wherein the beauty serum comprises at least one fermentation solution selected from Saccharomyces / Anzange ferment filtrate, Saccharomyces / Human (fibroblast / mononuclear cell) induced pluripotent cell culture conditioned medium ferment filtrate, Galactomyces / Eryngium multiflorum callus culture ferment filtrate, and a resin.

The present invention relates to a cosmetic composition comprising galactomyces, having skin-soothing, moisture-retaining, skin tone-enhancing, and skin barrier-improving properties, and more specifically, comprises a galatomyces fermentation filtrate, a rice lees distillate, sh-oligopeptide-1, a plant extract, a skin conditioning agent, a pH regulator, a surfactant, an emollient, a sequestering agent, a film-forming agent, and a thickener. The cosmetic composition comprising said ingredients is less likely to cause skin irritation by having a large amount of natural ingredients, is eco-friendly by upcycling rice lees, exhibits skin-soothing, moisture-retaining, skin tone-enhancing, and skin barrier-improving effects by containing an abundant amount of galactomyces, vitamins, minerals, and organic acid ingredients, and improves skin health by preventing skin aging and skin damage and promoting skin cell regeneration.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The invention discloses a beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H is as shown in SEQ ID NO. 3. The invention further discloses the application of the beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H in the preparation of lactose-N-tetrasaccharide. According to the invention, 1, 3-galactosyl transferase Pm beta 3GalT is subjected to mutation modification to obtain a mutant enzyme, and compared with a wild enzyme, the enzyme activity of the mutant enzyme is improved by 157.21% and is obviously improved, and the thermal stability and alkali resistance are also obviously improved. The beta 1, 3-galactosyl transferase Pm beta 3GalT-S207H disclosed by the invention has important theoretical value and application value on the industrial production of LNT (Lipoxystrobin).

The invention belongs to the field of pharmaceutical preparations. The invention relates to lipid nanoparticles modified by probiotic coupled galactose and coated with diammonium glycyrrhizinate, L-arginine and copper tannic acid nano enzyme as well as a preparation method and application of the lipid nanoparticles. The lipid nanoparticles prepared by coupling and wrapping the diammonium glycyrrhizinate, the L-arginine and the copper tannic acid nano-enzyme with the probiotics have good biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, the half-life period of a medicine circulating in a body can be prolonged, the inherent beneficial functions of the probiotics are cooperated, and the bioavailability of the medicine is improved. The potential application value is realized in the fields of treating the metabolic dysfunction related steatohepatitis and the like.

The invention belongs to the technical field of biomass conversion and functional food ingredients, and discloses a method for preparing galactooligosaccharide prebiotics from cellulose. The method comprises the following steps: mixing cellulose with a galactose aqueous solution, and drying to obtain galactose pre-impregnated cellulose; impregnating the cellulose pre-impregnated with galactose with an acid catalyst solution, and drying to obtain cellulose impregnated with galactose and an acid catalyst; carrying out solvent-free ball milling treatment on the cellulose impregnated with the galactose and the acid catalyst, so that the cellulose is synchronously subjected to depolymerization and grafting reaction with the galactose to obtain a crude product; and carrying out purification treatment on the crude product, and removing the residual acid catalyst to obtain the galactooligosaccharide prebiotics. According to the galactooligosaccharide prepared by the preparation method disclosed by the invention, the water solubility of the oligosaccharide is greatly improved due to the introduction of a galactose branched chain, the yield of a final product is high, and the prebiotic activity of the final product is equivalent to that of a high-cost enzymic method commercial product and even is better for a specific strain.

The invention discloses a preparation method of bio-based trans, trans-muconic acid. Comprising the following steps: mixing a raw material containing galactose diacid with a catalyst, and reacting to obtain a product containing trans, trans-muconic acid; the catalyst is selected from at least one of ammonium paramolybdate, ammonium orthomolybdate, potassium heptamolybdate, sodium molybdate, sodium molybdate and molybdic acid. Compared with a traditional method for synthesizing trans, trans-muconic acid, the method provided by the invention has the advantages of simple steps, low cost and high conversion rate selectivity. Compared with traditional fossil energy-based raw materials, the reaction raw materials are derived from biomass, and the sustainable development view and the dual-carbon concept are met.

The invention provides modified tartary buckwheat sprout acidic polysaccharide, a preparation method thereof and application of the modified tartary buckwheat sprout acidic polysaccharide in preparation of a medicine or health food with an immune enhancement function. The tartary buckwheat sprout acidic polysaccharide is rich in polygalacturonic acid (HG) and I-type polyrhamnogalacturonic acid (RG-I) pectin structural domains, and has remarkable in-vivo immune enhancement activity. The tartary buckwheat bud seedling acidic polysaccharide is subjected to structural targeting modification through a controllable partial acid hydrolysis technology and a directional enzyme digestion technology, and by comparing the in-vivo immune enhancement activity of the tartary buckwheat bud seedling acidic polysaccharide before and after targeting modification, it is found that the immune enhancement activity of the tartary buckwheat bud seedling modified acidic polysaccharide is remarkably superior to that of the tartary buckwheat bud seedling acidic polysaccharide.

This invention discloses a high-yield lactyl-3-4 ...5-4-4-4-4-4- N This invention relates to plasmid-free genetically engineered strains of tetrasaccharides and their applications, belonging to the field of microbial genetic engineering. The invention screened strains with higher activity. β -1,3-galactosyltransferase gene PmgalT Computer-aided enzyme function modification was used to achieve a shake-flask yield of 10.05 g / L for the constructed mutant. Subsequently, genome integration was performed... breast Multi-copy integration PmgalT * V27I / V39I / Y147F ‑galE‑galU A plasmid-free strain was constructed, enabling it to grow in shake flasks with lactoyl- N The yield of tetrasaccharides reached 14.4 g / L. Using glucose as the sole carbon source, the highest yield of 68.19 g / L was achieved at 64.5 h; using glycerol as the sole carbon source, the highest yield of 62.88 g / L was achieved at 60.5 h, providing a basis for its industrial production.

The invention belongs to the field of food science and engineering, and discloses a preparation method of an active medicinal and edible composite nutrient AMCN with an anti-aging effect, and the preparation method comprises the following steps: putting a ganoderma lucidum monoclonal strain into a liquid culture medium for controllable culture to obtain supernate with beta-glucosidase activity of over 100mU / mL; and adding rhizoma polygonati powder, lucid ganoderma powder and mulberry leaf powder, carrying out enzymatic biotransformation, carrying out lactobacillus plantarum fermentation, adding a freeze-drying protective additive, carrying out freeze-drying, grinding to obtain the active medicinal and edible composite nutrient AMCN, and storing the finished product in a dry and dark place. The active medicinal and edible composite nutrient can be used for preparing anti-aging functional foods or nutritional health-care products. A D-galactose induced zebrafish aging model verifies that the active medicinal and edible composite nutrient prepared by the application plays an anti-aging role by relieving oxidative stress, inhibiting cell aging and maintaining telomere stability, can reduce beta-galactosidase activity and intracellular ROS (reactive oxygen species) level, improves telomerase protein concentration, and has a good anti-aging effect. And the telomere length can be effectively recovered by medium and high concentrations.

This invention belongs to the field of vertebrate technology, specifically relating to a method for constructing a complex inflammatory animal model in middle-aged and elderly individuals and its related applications. The method includes: selecting adult animals for adaptive feeding, daily subcutaneous injection of D-galactose to establish a susceptibility to aging and oxidative stress, and administering sodium dextran sulfate (DSS) solution within a specific time window to induce intestinal inflammation, forming a complex inflammatory state through gut-hepatic axis interactions. The constructed animal model simultaneously exhibits intestinal inflammatory damage, abnormal hepatic oxidative stress, and aging-related characteristics, realistically simulating the pathological process of gut-hepatic axis dysfunction in middle-aged and elderly individuals. This model is suitable for screening and evaluating drugs, medical nutrition products, and functional foods that improve gut-hepatic axis dysfunction, providing a reliable technical platform for research on related disease mechanisms and the development of interventional substances.

The invention provides a preparation method of an alpha-2, 3 sialic acid glycosyl transferase mediated sugar chain fixed-point coupling antibody drug conjugate, which comprises the following steps: S1, dissolving an antibody, adding UDP-Gal, Mn < 2 + > and beta-1, 4 galactosyl transferase for reaction, and purifying after reaction to obtain an antibody I with galactose at the tail end of a sugar chain; s2, dissolving the antibody I, adding an azide-modified CMP sialic acid derivative, alpha-2, 3 sialic acid glycosyltransferase and alkaline phosphatase for reaction, and purifying after reaction to obtain an antibody II of which the tail end of a carbohydrate chain is connected with the sialic acid derivative; s3, dissolving toxin molecules in DMSO, adding the dissolved toxin molecules into the antibody II for reaction, and performing ultrafiltration after the reaction to obtain ADC molecules; or the ADC molecule is directly prepared by adopting a one-pot enzyme method. The screened ST3Gal3 is used for preparing the carbohydrate chain fixed-point coupling ADC, the DAR value is controllable, batch-to-batch stability is achieved, uniformity is high, repeatability is high, quality control and CMC are better, and then the drug effect of the ADC can be better improved.

An object is to provide a method for effectively utilizing byproducts of the production of dairy products. Another object is to provide a method for producing galactosylkojibiose having a superior prebiotic ability. Another object is to provide a solution or composition comprising galactosylkojibiose, wherein at least 80% of galactosylkojibiose is maintained even after heated. A method for producing a composition comprising an oligosaccharide, the method comprising the step of allowing a glucansucrase to act on a composition comprising lactose and sucrose to obtain a composition comprising galactosylkojibiose is provided. It is preferable to use a lactic acid bacterium that constitutively expresses a membrane-bound type glucansucrase. There are provided a solution containing galactosylkojibiose, which has a pH lower than 7, and a composition comprising galactosylkojibiose, wherein when the composition is made into a solution having a solid content concentration of 10 to 80%, the solution has a pH lower than 7.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

The invention belongs to the technical field of biological medicine, and particularly relates to a diglycerol linolenate galactoside compound in pepper as well as a preparation method and application of the diglycerol linolenate galactoside compound. The preparation method comprises the following steps: (1) taking red peppers to prepare pretreated red peppers; (2) adding the pretreated red peppers into an ethanol solution, performing ultrasonic extraction, and collecting first filtrate and first filter residues; (3) adding an ethanol solution into the first filter residue, carrying out ultrasonic extraction, combining the first filtrate and the second filtrate, and concentrating to obtain a crude extract; (4) separating the crude extract by adopting high-speed counter-current chromatography to obtain a primary purified product; and (5) further separating and purifying the primary purified product by adopting high performance liquid chromatography, and identifying to obtain the diglycerol linolenate galactoside compound. The purity of the diglycerol linolenate galactoside compound obtained by the preparation method is as high as 99.3%, and the diglycerol linolenate galactoside compound has a remarkable scavenging effect on DPPH free radicals, shows good antioxidant activity and has a wide application prospect.